Premium-price biologicals and novel therapies will drive psoriatic arthritis market growth

10 September 2014

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to 2023 forecast period.

According to a new report from Decision Resources Group, in 2013, five marketed TNF-alpha inhibitors dominated sales in the PsA market with over 90% of the $2.3 billion major-market total; adalimumab (AbbVie/Eisai’s Humira) was the overall sales leader.

Over the next decade, TNF-alpha inhibitors will retain their sales-leading position, but recently launched treatments ustekinumab (Janssen’s Stelara) and apremilast (Celgene’s Otezla), together with novel therapies - which include the anti-interleukin-17 monoclonal antibodies secukinumab (Novartis), ixekizumab (Eli Lilly), and brodalumab (Amgen/AstraZeneca/Kyowa Hakko Kirin) and the Janus-kinase inhibitor tofacitinib (Pfizer’s Xeljanz) - will account for around 21% of 2023 PsA sales combined in the USA, France, Germany, Italy, Spain, UK and Japan.

Other key findings from the Pharmacor report, titled Psoriatic Arthritis, are:

Novel oral therapies address “stop gap” needs: Of the five agents entering the PsA market, tofacitinib (Pfizer’s Xeljanz) will experience the most uptake during the forecast period. Tofacitinib and recently launched apremilast feature oral formulations and unique mechanisms of action, thus allowing them to compete for TNF-alpha inhibitor-refractory patients, as well as experience uptake as “stop gaps” for conventional DMARD failures before stepping up to treatment with biologics.
Biosimilars will modulate sales growth: Less-expensive biosimilar versions of several biologics will launch beginning in 2015 and will erode biologics’ sales through 2023, with the largest impact on the TNF-alpha inhibitor class.
Current therapies remain relevant: Interviewed thought leaders report that conventional DMARDs and TNF-alpha inhibitors are the clinical mainstays for mild and moderate-to-severe PsA, respectively, and will face only moderate loss of patient shares to recently launched and incoming novel therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK